RAPP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rapport Therapeutics Inc (RAPP) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the technical indicators show some bullish momentum, the lack of significant positive catalysts, weak financial performance, and absence of recent news or influential trading activity suggest that the stock does not currently present a compelling investment opportunity.
The stock is showing bullish momentum with MACD positive and expanding, RSI neutral at 58.906, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 31.005 and 32.189, while support levels are at 27.169 and 25.985. However, the stock trend analysis suggests limited short-term upside with a 50% chance to decrease by -1.29% in the next day and -0.43% in the next week.
Analyst coverage from Wells Fargo initiated with an Overweight rating and a $43 price target, citing potential best-in-category efficacy in focal onset seizures. Technical indicators show bullish momentum.
Congress trading data and insider/hedge fund activity are neutral with no significant trends.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$26.93M (improved by 53.53% YoY), and an EPS of -0.71 (improved by 42% YoY). Gross margin remains at 0%. Overall, the financials indicate a lack of profitability and growth.
Wells Fargo initiated coverage with an Overweight rating and a $43 price target, citing confidence in the company's Phase 2a data for focal onset seizures. This suggests optimism about the company's potential in the biotech space.
